[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

doi:10.1016/j.bulcan.2019.11.016

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].

Bulletin du cancer - 1 Apr 2020

Cohen Romain, Pudlarz Thomas, Garcia-Larnicol Marie-Line, Vernerey Dewi, Dray Xavier, Clavel Léa, Jary Marine, Piessen Guillaume, Zaanan Aziz, Aparicio Thomas, Louvet Christophe, Tournigand Christophe, Chibaudel Benoist, Tougeron David, Guimbaud Rosine, Benouna Jaafar, Adenis Antoine, Sokol Harry, Borg Christophe, Duval Alex, Svrcek Magali, André Thierry

Abstract excerpt

INTRODUCTION: Perioperative chemotherapy is the standard strategy for localized gastric cancers. Nevertheless, this strategy seems to be inefficient, if not deleterious, for patients with tumors harboring microsatellite instability (MSI) and/or mismatch repair deficiency (dMMR), a tumor phenotype predictive for the efficacy of immune checkpoint inhibitors (ICKi). AIM: The GERCOR NEONIPIGA single-arm phase II...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Immunological

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Chemotherapy, Adjuvant

Share to Clinical Trials, Phase II as Topic

Share to Ipilimumab

Share to Multicenter Studies as Topic

Share to Neoadjuvant Therapy

Share to Nivolumab

Share to Patient Selection

Source

Open in PubMed

Identifiers

PMID: 32057467
DOI: 10.1016/j.bulcan.2019.11.016

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].PMID 32057467Read ↗

A randomized, open, multicenter Phase II study to explore the sequential use of chemotherapy and immunotherapy in postoperative adjuvant therapy for gastric or esophagogastric junction adenocarcinoma or colorectal adenocarcinoma with radical resection of POLE/POLD1 gene mutation or dMMR/MSI-HSemantic proximity Read ↗

Efficacy and safety of neoadjuvant toripalimab plus chemotherapy in localized deficient mismatch repair/microsatellite instability-high gastric or esophagogastric junction adenocarcinoma (NICE): a multicentre, single-arm, exploratory phase 2 studySemantic proximity Read ↗

Mutations of PI3K-AKT-mTOR Pathway as Predictors for Immune Cell Infiltration and Immunotherapy Efficacy in dMMR/MSI-H Gastric AdenocarcinomaSemantic proximity Read ↗

The impact of microsatellite instability in patients with locally advanced resectable gastric cancer undergoing perioperative therapySemantic proximity Read ↗

Tremelimumab and durvalumab as neoadjuvant or non-operative management strategy of patients with microsatellite instability-high resectable gastric or gastroesophageal junction adenocarcinoma: the INFINITY study by GONOSemantic proximity Read ↗

Potent therapeutic strategy in gastric cancer with microsatellite instability-high and/or deficient mismatch repairSemantic proximity Read ↗

Mutations of PI3K-AKT-mTOR pathway as predictors for immune cell infiltration and immunotherapy efficacy in dMMR/MSI-H gastric adenocarcinoma.Semantic proximity Read ↗

Efficacy and safety of neoadjuvant immunotherapy in patients with microsatellite instability-high gastrointestinal malignancies: A case series.Semantic proximity Read ↗

Effects of perioperative treatment of resectable adenocarcinoma of esophagogastric junction by immunotherapy (Adebrelimab) combined with chemotherapy (XELOX): protocol for a single-center, open-labeled study (AEGIS trial, neoadjuvant immunochemotherapy)Semantic proximity Read ↗

Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.Semantic proximity Read ↗

New directions in perioperative management of locally advanced esophagogastric cancer.Semantic proximity Read ↗

Perioperative chemotherapy with or without epidermal growth factor receptor blockade in unselected patients with locally advanced oesophagogastric adenocarcinoma: Randomized phase II study with advanced biomarker program of the German Cancer Society (AIO/CAO STO-0801).Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.